Early Trading Has Brooklyn ImmunoTherapeutics (BTX) Climbing for June 23

Equities Staff  |

Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) has already risen $0.0385 in early trading Thursday.

After closing the previous trading session at $0.52, Brooklyn ImmunoTherapeutics has moved 7.34% higher ahead of market open.

The company is down 3.62% over the last 5 days.

Today could shape up to be an interesting day for Brooklyn ImmunoTherapeutics investors.

For technical charts, analysis, and more on Brooklyn ImmunoTherapeutics Inc visit the company profile.

Pre-market prices and movements as of 08:02:14 est.

About Brooklyn ImmunoTherapeutics Inc

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

To get more information on Brooklyn ImmunoTherapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Brooklyn ImmunoTherapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content